Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
Cash to Debt 1.37
GNOM's Cash to Debt is ranked lower than
63% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. GNOM: 1.37 )
GNOM' s 10-Year Cash to Debt Range
Min: 0.34   Max: 5.3
Current: 1.37

0.34
5.3
Interest Coverage -25.40
GNOM's Interest Coverage is ranked lower than
140% of the 408 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GNOM: -25.40 )
GNOM' s 10-Year Interest Coverage Range
Min: -25   Max: -10
Current: -25.4

-25
-10
F-Score: 3
M-Score: -1.94
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
Operating margin (%) -358.20
GNOM's Operating margin (%) is ranked lower than
72% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. GNOM: -358.20 )
GNOM' s 10-Year Operating margin (%) Range
Min: -5390.9   Max: -358.2
Current: -358.2

-5390.9
-358.2
Net-margin (%) -374.00
GNOM's Net-margin (%) is ranked lower than
72% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. GNOM: -374.00 )
GNOM' s 10-Year Net-margin (%) Range
Min: -5770.3   Max: -374
Current: -374

-5770.3
-374
ROE (%) -87.60
GNOM's ROE (%) is ranked lower than
70% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -20.60 vs. GNOM: -87.60 )
GNOM' s 10-Year ROE (%) Range
Min: -87.6   Max: -78.3
Current: -87.6

-87.6
-78.3
ROA (%) -55.60
GNOM's ROA (%) is ranked lower than
64% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. GNOM: -55.60 )
GNOM' s 10-Year ROA (%) Range
Min: -118.7   Max: -55.6
Current: -55.6

-118.7
-55.6
ROC (Joel Greenblatt) (%) -278.00
GNOM's ROC (Joel Greenblatt) (%) is ranked lower than
66% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -243.56 vs. GNOM: -278.00 )
GNOM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -348   Max: -197.2
Current: -278

-348
-197.2
» GNOM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2012

GNOM Guru Trades in Q3 2012

Paul Tudor Jones Sold Out
» More
Q4 2012

GNOM Guru Trades in Q4 2012

Jean-Marie Eveillard 1,144,743 sh (New)
» More
Q1 2013

GNOM Guru Trades in Q1 2013

Jim Simons 63,478 sh (New)
Jean-Marie Eveillard Sold Out
» More
Q2 2013

GNOM Guru Trades in Q2 2013

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with GNOM

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2012-12-31 New Buy0.01%$2.92 - $3.16 $ 2.15-30%1144743
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.20
GNOM's P/B is ranked lower than
60% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 5.51 vs. GNOM: 2.20 )
GNOM' s 10-Year P/B Range
Min: 0.85   Max: 6.81
Current: 2.2

0.85
6.81
P/S 4.75
GNOM's P/S is ranked lower than
60% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 19.16 vs. GNOM: 4.75 )
GNOM' s 10-Year P/S Range
Min: 1.48   Max: 9.89
Current: 4.75

1.48
9.89
Current Ratio 1.06
GNOM's Current Ratio is ranked lower than
64% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. GNOM: 1.06 )
GNOM' s 10-Year Current Ratio Range
Min: 0   Max: 0
Current: 1.06

Quick Ratio 3.27
GNOM's Quick Ratio is ranked lower than
64% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. GNOM: 3.27 )
GNOM' s 10-Year Quick Ratio Range
Min: 0   Max: 0
Current: 3.27

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 10.80
GNOM's Price/Net Current Asset Value is ranked lower than
60% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 44.88 vs. GNOM: 10.80 )
GNOM' s 10-Year Price/Net Current Asset Value Range
Min: 6.9   Max: 41.3
Current: 10.8

6.9
41.3
Price/Tangible Book 2.30
GNOM's Price/Tangible Book is ranked lower than
60% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 8.78 vs. GNOM: 2.30 )
GNOM' s 10-Year Price/Tangible Book Range
Min: 1.2   Max: 3.7
Current: 2.3

1.2
3.7
Price/Median PS Value 0.70
GNOM's Price/Median PS Value is ranked lower than
60% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. GNOM: 0.70 )
GNOM' s 10-Year Price/Median PS Value Range
Min: 0.4   Max: 1.5
Current: 0.7

0.4
1.5

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
» More Articles for GNOM

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
No related articles found.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide